ACTEMRA is not covered on the Reformulary. Reformulary covers a preferred tocilizumab biosimilar that offers the same clinical value at a lower net cost to the plan. TYENNE requires Special Authorization.

Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.
 

ACTEMRA is used to treat  
Giant Cell Arteritis (GCA)
Juvenile Idiopathic Arthritis
Rheumatoid Arthritis